United States securities and exchange commission logo





                              September 22, 2020

       Eric A. Adams
       President and Chief Executive Officer
       InMed Pharmaceuticals Inc.
       Suite 310-815 W. Hastings Street
       Vancouver, B.C. V6C 1B4
       Canada

                                                        Re: InMed
Pharmaceuticals Inc.
                                                            Amendment No. 3 to
Registration Statement on Form S-1
                                                            Filed September 15,
2020
                                                            File No. 333-239319

       Dear Mr. Adams:

              We have reviewed your amended registration statement and have the
following
       comment. In our comment, we may ask you to provide us with information
so we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to the comment, we may have additional comments.

       Amendment No. 3 to Registration Statement on Form S-1 filed September
15, 2020

       Prospectus Summary
       Overview, page 2

   1.                                                   We note your disclosure
on page 4 that to date you have safety data with INM-755 in 22
                                                        healthy adult
volunteers and that a regulatory application was approved on April 17, 2020
                                                        for a second Phase 1
clinical trial in healthy volunteers. Please revise your pipeline table
                                                        and your Risk Factor on
page 29 to make it clear that your clinical development to date
                                                        has been conducted
outside the U.S.
 Eric A. Adams
InMed Pharmaceuticals Inc.
September 22, 2020
Page 2

       You may contact Ibolya Ignat at 202-551-3636 or Terence O'Brien at
202-551-3355 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jeffrey Gabor at 202-551-2544 or Christine Westbrook at 202-551-5019
with any other
questions.



                                                          Sincerely,
FirstName LastNameEric A. Adams
                                                          Division of
Corporation Finance
Comapany NameInMed Pharmaceuticals Inc.
                                                          Office of Life
Sciences
September 22, 2020 Page 2
cc:       Daniel M. Miller, Esq.
FirstName LastName